Abstract: Previous reports have described the appearance of systemic lupus erythematosus (SLE) cases following interferon-α (IFN-α) therapy, IFN-regulated gene expression is significantly increased in SLE, and an association between SLE and gene variants belonging to IFN downstream pathways has been shown. Based on this, targeting of IFN and of their signaling pathways has appeared to be interesting developments within the field of SLE therapy. Different specific type I IFN antagonists have been studied in clinical trials and some of those have already reached Phase III. A potential approach would be to target IFN receptors rather than IFN themselves. Anifrolumab (previously MEDI-546) is a fully human monoclonal antibody (Ab) that binds to subunit 1 of the type I IFN receptor (IFNAR1), blocking the action of different type I IFNs (IFN-α, IFN-β and IFN-ω) . This drug has been assessed in 11 clinical studies: 9 in SLE, 1 in systemic sclerosis and 1 in rheumatoid arthritis. In SLE, clinical development reached Phase I for 1 study and Phases II and III for 5 and 3 trials, respectively. The Phase IIb, randomized control trial (RCT), double-blind, placebo-controlled study of adults with moderate-to-severe SLE (MUSE trial) showed positive results on the composite primary endpoint SRI-4. Greater efficacy was seen in patients with high baseline IFN gene signature compared with those with low baseline IFN gene signature. Anifrolumab also demonstrated promising results on cutaneous and arthritic manifestations, especially among patients with a high IFN gene signature. The pivotal Treatment of Uncontrolled Lupus via the Interferon IFN Pathway (TULIP 1 and 2 studies are now completed. In August 2018, the promoter announced that the TULIP 1 Phase III trial did not reach its primary endpoint. The release of the completed but not yet published Phase II studies and of the TULIP pivotal trials results will further inform us on the actual therapeutic potential of anifrolumab.
Introduction
The last decades have been marked by a profound improvement in the prognosis of patients with systemic lupus erythematosus (SLE), thanks to changes in the pharmacopeia. 1 The survival is currently higher than 90% at 10 years in most dedicated centers. For 60 years, the only new treatment approved in the SLE has been belimumab, despite 74 targeted therapies being studied in SLE. 2 In parallel, new pathways involved in the physiopathology of SLE have emerged, leading to the recognition of interferons (IFNs) as critical mediators in SLE. Therefore, new therapeutic strategies targeting IFNs have been developed in SLE. http://doi.org/10.2147/DDDT.S170969
From IFNs to IFN-blocking strategies
IFNs have been discovered as antiviral cytokines in 1957. 4 About 20 subtypes have now been described and divided into three main families: type I, type II and type III. Type I IFNs represent the largest family, with IFN-α and IFN-β being involved in antiviral immunity but also in inflammatory pathways. 5 Several experiments of mouse models and SLE patients have highlighted the role of type I IFN and particularly IFN-α in SLE. Stimulation of the production of type I IFN in NZB/NZWF1 mice, one of the most interesting mouse models of SLE, by polyinosinic:polycytidylic acid, induces production of antinucleic acid antibodies and tissue damage. 6 Subsequently, the early observation of increased type I IFN levels in SLE patients was described. 7 Likewise, patients with carcinoid tumors treated with IFN therapy showed an increased incidence of autoimmune diseases such as SLE. 8 At the beginning of the 2000s, large gene transcripts induced by type I IFN has been characterized from the blood of SLE patients. 9, 10 Genome-wide association studies (GWASs) of SLE patients have thereafter identified the important role of gene variants encoding for proteins of the innate immune response, such as TLR-7, TLR-9, IRF-5, IRF-7 and IRF-8.
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In the recent past, it has been shown that Aicardi-Goutières syndrome, a disease related to the upregulation of type I IFN, shared several SLE features, leading to the identification of monogenic forms of SLE. 12 As a consequence, a group of different Mendelian diseases characterized by an upward regulation of type I IFN has emerged in 2011 and was termed "interferonopathies".
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IFN-I-induced gene transcripts signature is now extensively known as the "interferon signature". Genome-wide gene expression studies using microarrays led to an identification of a dysregulated expression of genes in the IFN pathway in about 50-75% of SLE patients. 9, 14 Type I IFN signaling pathway was found to be the most highly activated signaling pathway in whole blood of both pediatric and adult SLE patients. 15, 16 More recently, different sets of genes derived from genome-wide gene expression studies and validated by quantitative PCR were developed to measure IFN gene expression based on a limited number of genes. 9, [14] [15] [16] [17] [18] These sets of genes were used as quantitative 9, 15, 18 or qualitative scores (eg, high versus low IFN gene signature). [14] [15] [16] [17] A high IFN gene signature was found to be more frequently in patients with severe phenotypes such as involvement of the central nervous system, hematological disorders and/or renal disease. 9 Moreover, both quantitative and qualitative IFN scores were found to be associated with the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score. [16] [17] [18] Type I IFN proteins bind to the subunit 1 of type I IFN heterodimeric transmembrane receptor (IFNAR1). IFNAR is composed of the two subunits IFNAR1 and IFNAR2 that will activate Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2) (Figure 1 ). These kinases lead to the phosphorylation of IFNAR, resulting in the involvement of signal transducer and activator of transcription (STAT) proteins and then phosphorylation, dimerization and nuclear translocation of STAT. In the nucleus, STAT is a transcription factor which induces the expression of IFN-regulated genes (IRGs). 19 In this con- ). 26 Others report that IFNAR1-antagonist Ab binds to the subunit 1 of IFNAR1. [26] [27] [28] Anifrolumab induces rapid internalization of IFNAR1 from the surface of monocytes and thereby reduces the occurrence of heterodimerization with IFNAR2 and the setting up of the IFN signaling complex. By antagonizing the binding of the different IFNs to the IFNAR1 receptor, anifrolumab blocks STAT1 phosphorylation and IFN-stimulated response element (ISRE) activity. Dose-dependently, anifrolumab inhibits type I IFN production and the production in a lesser extent of some cytokines (TNF-α, IL-6 and IL-8 by 40-50%) and reduces CD80 and CD83 expression of dendritic cells by 30-50%. 29 Blockade of IFNAR1 also alters the type I IFN autoamplification, mediated by the cellintrinsic induction related to IFNAR activation. 30, 31 Anifrolumab also inhibits the differentiation of B-cells into plasma cells by interfering with the production of IFN.
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Anifrolumab administered at 300 mg intravenously every 4 weeks for 48 weeks is able to neutralize 85-90% of the IFN signature (median range) from 29 to 365 days. 32 Maximum concentration (Cmax) and exposure (AUC) of 300 mg and 600 mg SC anifrolumab change dose-proportionally. Peak serum concentrations are reached 4-7 days after injection. The exposure of 300 mg SC anifrolumab is about 87% of the intravenous (IV) one. Its concentrations are detectable for approximately 1 month postadministration and below the limit of detection by 84 days postdose. 33 Anifrolumab has been or is currently being studied in 11 different studies (Table 1) ). This trial included adults with moderate-to-severe SLE but, of note, neuropsychiatric SLE and lupus nephritis were exclusion criteria. Three hundred and five patients were randomized between IV dose of anifrolumab (300 mg or 1 g) and placebo. Doses were administrated every month for 48 weeks, as an add-on-therapy to SOC. A stratified randomization was applied according to oral glucocorticoid dosage (≥10 or <10 mg/day), SLEDAI-2K (≥10 or <10) and type I IFN gene signature results at baseline. The primary endpoint was the percentage of patient, both reaching a sustained reduction of oral corticosteroids and an SLE responder index (SRI-4) response at week 24. Notably, this primary endpoint was investigated in a modified intent-to-treat population as well as in the type I IFN-high subpopulation (2-sided type I error rate set to 0.10). The trial was considered positive if the primary endpoint was fulfilled in either of these 2 situations. At last, the percentage of patients who fulfilled the primary endpoint was higher in the anifrolumab group (34.3% for 300 mg, p=0.014 and 28.8% for 1 g, p=0.06) than the placebo group (17.6%). There was no significant difference between the groups in terms of global tolerance and safety despite a more frequent Herpes zoster reactivation (5.1% with 300 mg and 9.5% with 1 g versus 2.0% with placebo), and also more influenza in anifrolumab-treated patients.
Other Phase II studies include: NCT01559090, a Phase II, multicenter, open-label, dose-escalation study to evaluate the safety and tolerability of IV dose of anifrolumab in Japanese subjects with active SLE, has been completed. 35 The primary outcome was the description of the safety profile of anifrolumab at dosages up to 1,000 mg IV every 4 weeks for 48 weeks and 300 mg IV every 4 weeks for 156 weeks, among Japanese patients. Twenty patients were enrolled and 17 received treatment. IV anifrolumab was well tolerated with a decent safety profile at the dose of either 100, 300 or 1,000 mg. Noteworthy, a pulmonary embolism occurred 9 weeks after anifrolumab was stopped, and a cerebral infarction occurred in a patient with a history of previous cerebral vasculitis and two events of cerebral infarction. An obvious assessment of causality was not figured out for these two thrombotic events occurred during the study. There were no statistical trends to suggest dose-dependent safety. Throughout the study period, all patients suffered at least one AE, most of moderate intensity (grade 1 or 2). The most common AEs were nasopharyngitis (n=8, 47.1%), upper abdominal pain (n=4, 23.1%) and headache (n=3, 17.6%). 35 SLE disease activity seemed to improve after anifrolumab therapy. Nevertheless, in this noncontrolled versus placebo trial, it is difficult to draw efficacy conclusions.
NCT01753193, an open-label extension study to evaluate long-term safety and tolerability of IV anifrolumab in adult subjects with moderately-to-severely active SLE, has also been completed, with pending results.
Anifrolumab is also being tested in a Phase II trial for lupus nephritis and a Phase II trial using SC delivery in SLE.
NCT02547922, TULIP-LN1, a multicenter, doubleblind, placebo-controlled, RCT, Phase II study assessing the efficacy and safety of anifrolumab in active proliferative lupus nephritis, is currently ongoing (recruiting).
NCT02962960, a multicenter, randomized, doubleblind, placebo-controlled, Phase II study characterizing the PK, pharmacodynamics (PD) and safety of anifrolumab following SC administration in adult SLE subjects with type I IFN test high result and active skin manifestations, is currently ongoing (active, not recruiting).
Phase III clinical studies (NCT02446899, NCT02446912 and NCT02794285)
The pivotal TULIP (Treatment of Uncontrolled Lupus via the IFN Pathway) programme contains two Phase III clinical trials, TULIP 1 and TULIP 2, which were evaluating the efficacy and safety of anifrolumab versus placebo in DovePress moderate-to-severe active autoAb-positive SLE patients receiving SOC treatment. TULIP 1 (NCT02446899), a Phase III, multicenter, multinational, double-blind, placebo-controlled RCT, randomized 460 patients (1:2:2) to receive a fixed-dose IV infusion of 150 mg anifrolumab, 300 mg anifrolumab or placebo every 4 weeks. TULIP 2 (NCT02446912), a Phase III, multicenter, multinational, double-blind, placebo-controlled RCT, randomized 373 patients (1:1) to receive a fixed-dose IV infusion of 300 mg anifrolumab or placebo every 4 weeks.
These trials evaluate the effect of anifrolumab in lowering disease activity (assessed by the SRI-4) and the use of oral corticosteroids, improving skin manifestations (assessed by cutaneous lupus erythematosus disease area and severity index (CLASI), and reducing flares.
The SRI-4 is a composite endpoint, defined by the following criteria:
• Reduction from baseline of ≥4 points in the SLEDAI-2K; Importantly, the promoter announced on 31 August that the TULIP 1 Phase III trial did not meet the primary endpoint of a statistically significant reduction in disease activity in patients with SLE as measured by the SRI-4 at 12 months, but the detailed results are still pending. 36 In addition to the pivotal trials, anifrolumab is also being tested in a Phase III SLE long-term extension trial, TULIP SLE LTE (NCT02794285), a multicenter, multinational, double-blind, placebo-controlled extension study to characterize the long-term safety and tolerability of an IV anifrolumab-therapy versus placebo as an add-on to SOC, in moderate-to-severe active SLE who completed a TULIP 1 or 2 study through the 52-week double-blind treatment period.
Discussion
Previous studies have described the appearance of SLE cases following IFN-α-therapy, and IRGs expression is significantly increased in SLE and an association between SLE and gene variants belonging to IFN downstream pathways has been shown. Based on this, targeting of IFNs and of their signaling pathways has appeared to be interesting developments within the field of SLE therapy.
One of the important contemporary challenges in the management of SLE is developing more effective drugs on the grounds of the lack of efficient targeted therapies to treat the heterogeneous SLE manifestations. For 60 years, the only new treatment approved in the SLE has been belimumab. Crucial evaluations from investigators involved in RCTs have made it possible to emphasize the several obstacles to effective drug development in SLE. These barriers could be represented by SLE manifestations heterogeneity, incomplete PK/PD and dose evaluation before onset of broad RCTs, the addition of evaluated targeted therapies as an add-on-therapy to the SOC, the difficulties in managing background treatment in RCTs, inappropriate study design (in terms of size or duration) and probably also improper selection of primary endpoint. 37 Several other treatments with positive results in Phase II trials have recently failed to fulfill primary endpoint in SLE Phase III RCTs. Nevertheless, learning from these unsuccessful RCTs allowed improvements in RCT SLE design. On the grounds of those obstacles to efficient drug development from the Phase II RCTs, pivotal studies of belimumab 38, 39 included only anti-DNA seropositive SLE patients and used the SRI-4 as a new primary endpoint. Even though this approach of composite responder indices does not appear to be perfect, it also has uncomfortable limitations in the context of RCTs. Much labor of the scientific community to work on the development of more efficient endpoints for SLE RCTs might allow capturing clinically relevant treatment responses. Touma and Gladman have recently discussed the most common pitfalls in the selection of patients and endpoints. 40 Of note, the heterogeneity of lupus patients requires careful selection at inclusion to evaluate the therapeutic response of those with active lupus disease instead of the stigma of previous flares. This also implies the participation of expert centers used to assessing complex lupus patients and the training of investigators in the use of multiple disease activity instruments. As far as endpoints are concerned, reproducible and reliable criteria have to be 22, 45 In the anifrolumab Phase II study, the SRI-4 response proportions, in the high IFN gene signature population, were 52.0% for the anifrolumab 300 mg group (p<0.001), 38.5% for the 1 g group (p=0.013) and 19.7% for placebo. Conversely, in the patients with a low IFN gene signature subgroup, no significant differences from placebo were seen. However, observed differences were rather due to an important difference in placebo effects between these two groups (high versus low IFN signature) than different response rates to anifrolumab in both subgroups. 22 More recently, a post-hoc analysis compared anifrolumab 300 mg with placebo on arthritis and rash measures using different outcomes. 46 Skin involvement was assessed using two non-specific tools SLEDAI-2K and BILAG and one specific tool the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI). 47 A ≥50% decrease from baseline at week 52 of mCLASI (modified CLASI excluding oral ulcer and alopecia without scalp inflammation) was used to define cutaneous improvement. Using both mCLASI and nonspecific tools, a significant improvement of cutaneous involvement was observed in anifrolumab-treated patients compared with placebo in the high IFN gene signature subgroup. Conversely, there was no significant difference between anifrolumab and placebo for skin improvement using SLEDAI-2K and mCLASI in the low IFN gene signature subgroup. Moreover, improvement in arthritis was assessed using SLEDAI-2K and BILAG. Again, a significant improvement of arthritis was observed with anifrolumab 300 mg compared with placebo in the high but not in the low IFN gene signature subgroup. 46 These results suggested that patients with high IFN gene signature may represent a population more likely to benefit from the add-on anifrolumab therapy to SOC. It is conceivable that this stronger effect on patients with IFN could restrict the use of anifrolumab to these patients. Routine search for the presence of an IFN signature is not currently widely available. However, it is hoped that ultrasensitive IFN assay techniques will become routinely available in the near future. This would likely allow the selection of patients who may benefit from anifrolumab. Anifrolumab is one of the more advanced drugs currently in the SLE pipeline. The release of the completed TULIP pivotal trials will inform us of its ability to confirm the hopes that were gleaned from its positive Phase IIb results and its positioning in the SLE armamentarium.
Conclusion
Targeting directly IFN receptors and blocking the action of all type I IFNs (IFN-α, IFN-β and IFN-ω) appear to be of potential interest in SLE. Anifrolumab (previously MEDI-546), a fully human monoclonal antibody that binds to subunit 1 of IFNAR1, showed promising preliminary results in its Phase IIb trial. The TULIP 1 Phase III trial did not meet its primary endpoint. The results of subsequent Phase II and Phase III trials are pending and will tell us more about the potential of anifrolumab as a new SLE treatment.
